Long-term treatment with an ACE inhibitor or an AT1 antagonist avoids hypertension-induced inflammation in the kidney

Journal of Nephrology

Volumn 19, Issue 6, 2006, Pages 725-731

  Esteban, Vanesa ^a   Gallego Delgado, Julio ^a   Lázaro, Alberto ^a   Osende, Julio ^b   Mezzano, Sergio ^c   Egido, Jesus ^a   Ruiz Ortega, Marta ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

Author keywords

ACE inhibition; Angiotensin; Inflammation; Kidney; NF B; Receptors

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; QUINAPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DRUG INHIBITION; FOLLOW UP; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; HISTOPATHOLOGY; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; KIDNEY DISEASE; KIDNEY INJURY; KOLETSKY RAT; LONG TERM CARE; NONHUMAN; QUANTITATIVE ANALYSIS; RAT; SYSTOLIC BLOOD PRESSURE; UNINEPHRECTOMY; UPREGULATION; WISTAR KYOTO RAT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; HYPERTENSION; INFLAMMATION MEDIATORS; LOSARTAN; NEPHRITIS; RATS; RATS, INBRED SHR; RATS, INBRED WKY; TETRAHYDROISOQUINOLINES; TIME FACTORS; UP-REGULATION;

EID: 33947254096     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Ruiz-Ortega M, Ruperez M, Esteban V, Rodriguez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J. Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney. Nephrol Dial Transplant 2006; 2: 16-20.
2. Wolf G, Ziyadeh FN, Thaiss F, Tomaszewski J, Caron RJ, Wenzel U, Zahner G, Helmchen U, Stahl RA. Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells: role of the angiotensin type 2 receptor. J Clin Invest 1997; 100: 1047-58.
3. Ruiz-Ortega M, Lorenzo O, Ruperez M, Blanco J, Egido J. Systemic infusion of angiotensin II into normal rats activates nuclear factor-kappaB and AP-1 in the kidney: role of AT (1) and AT(2) receptors. Am J Pathol 2001; 158: 1743-56.
4. Wolf G, Wenzel U, Burns KD, Harris RC, Stahl RA, Thaiss F. Angiotensin II activates nuclear transcription factor-kB through AT1 and AT2 receptors. Kidney Int 2002; 61: 1986-95.
5. Mezzano S, Aros C, Droguett A, Burgos ME, Ardiles L, Flores C, Schneider H, Ruiz-Ortega M, Egido J. NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant 2004; 19: 2505-12.
6. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005; 67: 799-812.
7. Esteban V, Lorenzo O, Ruperez M, Suzuki Y, Mezzano S, Blanco J, Kretzler M, Sugaya T, Egido J, Ruiz-Ortega M. Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J Am Soc Nephrol 2004; 15: 1514-29.
8. Guijarro C, Egido J. Transcription factor-kappa B (NF-kappa B) and renal disease. Kidney Int 2001; 59: 415-24.
9. Nemoto K, Sekimoto M, Fukamachi K, Kageyama H, Degawa M, Hamadai M, Hendley ED, Macrae IM, Clark JS, Dominiczak AF, Ueyama T. No involvement of the nerve growth factor gene locus in hypertension in spontaneously hypertensive rats. Hypertens Res 2005; 28: 155-63.
10. Geiger H, Fierlbeck W, Mai M, Ruchti H, Schonfeld V, Dammrich J, Hugo C, Neumayer HH. Effects of early and late antihypertensive treatment on extracellular matriz proteins and mononuclear cells in uninephrectomized SHR. Kidney Int 1997; 51: 750-61.
11. Rodriguez-Iturbe B, Quiroz Y, Ferrebuz A, Parra G, Vaziri ND. Evolution of renal interstitial inflammation and NF-kappaB activation in spontaneously hypertensive rats. Am J Nephrol 2004; 24: 587-94.
12. Sanz-Rosa D, Cediel E, de las Heras N, Miana M, Balfagon G, Lahera V, Cachofeiro V. Participation of aldosterone in the vascular inflammatory response of spontaneously hypertensive rats: role of the NFkappaB/ IkappaB system. J Hypertens 2005; 23: 1167-72.
13. Wolf G, Schneider A, Helmchen UM, Stahl RA. AT1-receptor antagonist abolish glomerular MCP-1 expression in a model of mesangial proliferative glomerulonephritis. Exp Nephrol 1998; 6: 112-20.
14. Ruiz-Ortega M, Ruperez M, Lorenzo O, Esteban V, Blanco J, Mezzano S, Egido J. Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int 2002; 82: 12-22.
15. Morrissey JJ, Klahr S. Differential effects of ACE and AT1 receptor inhibition on chemoattractant and adhesion molecule synthesis. Am J Physiol 1998; 274: F580-6.
16. Esteban V, Ruperez M, Vita JR, Lopez ES, Mezzano S, Plaza JJ, Egido J, Ruiz-Ortega M. Effect of simultaneous blockade of AT1 and AT2 receptors on the NFkappaB pathway and renal inflammatory response. Kidney Int 2003; 86: S33-8.
17. Piqueras L, Kubes P, Alvarez A, O'Connor E, Issekutz AC, Esplugues JV, Sanz MJ. Angiotensin II induces leukocyte-endothelial cell interactions in vivo via AT1 and AT2 receptor-mediated P-selectin upregulation. Circulation 2000; 102: 2118-23.
18. Sironi L, Gelosa P, Guerrini U, Banfi C, Crippa V, Brioschi M, Gianazza E, Nobili E, Gianella A, de Gasparo M, Tremoli E. Anti-inflammatory effects of AT1 receptor blockade provide end-organ protection in stroke-prone rats independently from blood pressure fall. J Pharmacol Exp Ther 2094; 311: 989-95.
19. Gasic S, Wagner OF, Fasching P, Ludwig C, Veitl M, Kapiotis S, Jilma B. Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type II diabetic patients with microalbuminuria. Am J Hypertens 1999; 12: 217-22.
20. Schalkwijk CG, Smulders RA, Lambert J, Donker AJ, Stehouwer CD. ACE-inhibition modulates some endothelial functions in healthy subjects and in normotensive type 1 diabetic patients. Eur J Clin Invest 2000; 30: 853-60.
21. Hlubocka Z, Umnerova V, Heller S, Peleska J, Jindra A, Jachymova M, Kvasnicka J, Horky K, Aschermann M. Circulating intercellular cell adhesion molecule-1, endothelin-1 and von Willebrand factor-markers of endothelial dysfunction in uncomplicated essential hypertension: the effect of treatment with ACE inhibitors. J Hum Hypertens 2002; 16: 557-62.
22. Rosei EA, Rizzoni D, Muiesan ML, Sleiman I, Salvetti M, Monteduro C, Porteri E; CENTRO (Candesartan on Atherosclerotic Risk factors) study investigators. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus. J Hypertens 2005; 23: 435-44.
23. Jilma B, Li-Saw-Hee FL, Wagner OF, Beevers DG, Lip GY. Effects of enalapril and losartan on circulating adhesion molecules and monocyte chemotactic protein-1. Clin Sci (Lond) 2002; 103: 131-6.
24. Nomura S, Shouzu A, Omoto S, Nishikawa M, Iwasaka T. Effects of losartan and simvastatin on monocyte-derived microparticles in hypertensive patients with and without type 2 diabetes mellitus. Clin Appl Thromb Hemost 2004; 10: 133-41.